MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

MediciNova (MNOV) was notified by Sanofi (SNY) that the Sanofi/Novartis (NVS) litigation was settled. Accordingly, MediciNova is entitled to ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its ...

Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given ...

Novartis (NVS) stock slips despite better than expected Q3 results amid concerns over a cancer drug added with its $3B ...

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and ...